(efgartigimod alfa + hyaluronidase (human recombinant))

all catalysts(0)

nothing on the calendar yet

News(4)

• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 6d ago
• Argenx jumps on Phase 3 data for blockbuster Vyvgart
  The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
  biopharma_dive · 1mo ago
• Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
  Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug
  endpoints · 1mo ago
• Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
  The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
  biospace · 2mo ago